Cerebrolysin

Cerebrolysin at a Glance

Cerebrolysin is not a single peptide but a mixture — a standardised enzymatic digest of purified porcine brain protein, containing low-molecular-weight peptides and free amino acids. That composition makes it unlike anything else in this category: it is a biological extract rather than a defined molecule, and batch consistency is a manufacturing question rather than a chemical one. It is given by injection and is a prescription medicine across parts of Europe and Asia for stroke, traumatic brain injury and dementia, with no FDA or EMA approval.

History & Development

Cerebrolysin is unlike anything else on this hub: not a peptide but a mixture, made by digesting pig brain, and prescribed in dozens of countries while remaining unapproved in the US and EU.

First described	Not established in the sources consulted for this section
Discovered / synthesised by	Not established in the sources consulted for this section
Institution	Not established in the sources consulted for this section
Origin	Proprietary preparation of low-molecular-weight peptides (below ~10 kDa) and free amino acids, produced by enzymatic breakdown of purified porcine brain protein
Key patent	Not established in the sources consulted for this section
Assignee	Not established in the sources consulted for this section
Development status	Prescription medicine in parts of Europe and Asia; not approved by the FDA or EMA

Discovery

The premise is old-fashioned and predates the era of single-target drug design: if brain tissue contains the factors that support neurons, then a purified digest of brain tissue might supply them. Cerebrolysin is that idea industrialised - porcine brain protein broken down enzymatically into peptides under roughly 10 kDa plus free amino acids, standardised as a proprietary preparation and marketed as a neurotrophic agent.

It cannot be characterised the way the rest of this hub can. There is no sequence, no molecular weight, no single receptor - which means batch-to-batch consistency rests on the manufacturing process rather than on chemical identity, and mechanism can only be described in general terms.

Development & ownership

Cerebrolysin has a substantial trial record, concentrated in the indications where it is prescribed. Neurorecovery after moderate-to-severe traumatic brain injury rests on the CAPTAIN I and II randomized trials and their prospective meta-analysis; motor and functional recovery after stroke rests on the CARS randomized trials and pooled analyses.

The counterweight is the 2023 Cochrane review in acute ischaemic stroke, which found - at moderate certainty - a probable increase in non-fatal serious adverse events. That is an unusual finding for a compound generally reported as well tolerated, and it belongs in the development record rather than only in the safety section.

Its regulatory position reflects that split: routine prescription across parts of Europe and Asia, and no approval from either the FDA or the EMA.

How it reached the market

Cerebrolysin is a physician-administered injectable, given as 10-50 mL by intravenous infusion or intramuscular injection in courses of 10-21 days. It is not a supplement anywhere, and it is not self-administrable. Its porcine-tissue origin is also a consideration that does not arise with a synthetic peptide - both for transmissible-agent risk and for anyone avoiding pig-derived products.

What It's Used For

Cerebrolysin is not a single peptide. It is a proprietary preparation of low-molecular-weight peptides (below roughly 10 kDa) and free amino acids produced by the enzymatic breakdown of purified porcine (pig) brain protein, marketed as a neurotrophic/neuroprotective injectable and given intravenously or intramuscularly. That makes it an outlier in this section twice over: it is animal-derived rather than lab-synthesized, and it has a genuinely large human evidence base — dozens of randomized controlled trials and repeated Cochrane reviews — so the question here is not the usual “any human data at all?” but how good and how consistent that data is. The answer is: unsettled. The most coherent signals are neurorecovery after moderate-to-severe traumatic brain injury and motor recovery during stroke rehabilitation, with weaker human signals in vascular dementia, Alzheimer’s disease, subarachnoid hemorrhage and pediatric neurodevelopment, and one animal-only application. Three caveats run through all of it and should color every row below: much of the supporting literature is manufacturer-supported, it is geographically concentrated (China, Russia, Eastern Europe), and it is repeatedly graded at high risk of bias. The one large, independently adjudicated question — does it save lives after acute ischemic stroke — has been answered no.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Traumatic brain injury (neurorecovery)Promising60%Human RCTs (CAPTAIN I/II) + prospective meta + 2023 systematic review. Small, single-region, no mortality benefit.

02Stroke recovery / neurorehabilitationPromising52%Human RCTs (CARS-1/2) + manufacturer meta-analyses positive on motor recovery; an independent meta was null on mRS/Barthel.

03Vascular dementiaPromising48%Cochrane 2019: 6 RCTs, benefit on cognition + global function — but graded very low quality, high risk of bias.

04Alzheimer’s diseaseShaky44%Meta-analysis of 6 double-blind RCTs; benefit at 4 weeks, durability at 6 months uncertain.

05Subarachnoid hemorrhageShaky36%2023 meta suggests lower mortality; the single dedicated pilot RCT was null on its functional endpoint.

06Pediatric neurodevelopmentShaky32%Two small single-center human RCTs (cerebral palsy; high-risk preterm infants). No replication.

07Diabetic peripheral neuropathyShaky18%One mouse model, intraperitoneal route. No human trial of any kind.

Mechanisms

Pharmacokinetics

Cerebrolysin is given only by injection — intravenous infusion (usually diluted in saline) or intramuscular injection. It is a mixture of peptides and free amino acids with negligible oral bioavailability, there is no oral formulation, and an oral product could not deliver the intact peptide fractions; route is therefore load-bearing for every finding here. Dosing in trials is by course rather than chronic administration: typically 10–50 mL/day for 10–21 days, sometimes repeated in cycles (the CAPTAIN TBI protocol used 50 mL/day for 10 days followed by two 10 mL/day cycles) ^{9,10Reference 9Poon W et al. · 2020RCTSafety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — human (RCT)View study →Reference 10Muresanu DF et al. · 2020RCTEfficacy and safety of Cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial — human (RCT)View study →}. Because it is a heterogeneous biological preparation rather than a single molecule, it has no single defined half-life and no clean pharmacokinetic profile — the proposed active principle is transient neurotrophic-like activity of its peptide fractions, and preclinical work indicates its constituents can influence blood-brain-barrier integrity ^{23Reference 23Rejdak K et al. · 2023ReviewModulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of Cerebrolysin — reviewView study →}. It is supplied as a sterile ampoule solution for parenteral use and requires the manufacturer’s storage handling.

Clinical & regulatory status

Cerebrolysin is an approved prescription medicine in a number of countries — Russia, China, several Eastern European and post-Soviet states, and parts of Asia — where it is indicated for acute ischemic stroke, vascular dementia, Alzheimer’s disease and traumatic brain injury. It is manufactured by EVER Neuro Pharma (Austria, formerly Ebewe Pharma). It is not approved by the US FDA, not approved by the EMA for these indications, and is not a dietary supplement anywhere. That split is the single most misrepresented fact about this compound: prescription status abroad is not US or EU approval. Registered trial activity remains substantial — ClinicalTrials.gov lists roughly 42 studies concentrated in stroke, TBI, dementia and subarachnoid hemorrhage, with several still recruiting. The counts below reflect what is findable and verifiable in PubMed and English-language registries in this pass; the Russian- and Chinese-language clinical literature is larger but not independently verifiable here.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status. Cerebrolysin occupies an unusual dual position. It is a genuine approved prescription medicine in Russia, China, several Eastern European and post-Soviet countries, and parts of Asia, prescribed there for acute ischemic stroke, vascular dementia, Alzheimer’s disease and traumatic brain injury. It is not approved by the US FDA, not approved by the EMA for these indications in Western Europe, and is not a dietary supplement in any jurisdiction. In the US it can only legitimately reach a patient as a physician-administered investigational or personally imported product; material bought online for self-injection is unapproved and unregulated. Prescription status abroad is not, and should never be presented as, Western approval.

How it’s supplied & administered. Cerebrolysin is supplied as a sterile solution in ampoules for parenteral use only — IV infusion or IM injection. There is no oral form, and oral dosing would not deliver the intact active fractions. Clinical courses run 10–50 mL/day for 10–21 days, sometimes in repeated cycles, and are administered by a clinician in every trial here. Ampoules require the storage handling specified on the manufacturer’s label.

Sourcing reality (this is a safety issue, not a footnote). Outside the countries where it is a registered prescription drug, Cerebrolysin reaches users through gray-market and research-chemical vendors with no manufacturing oversight. Because it is injected, those risks are serious: counterfeit or mislabeled product, incorrect concentration, endotoxin or pyrogen contamination, and non-sterile handling. There is a documented market of competing “Cerebrolysin-like” brain-hydrolysate preparations whose biological activity and composition differ from the reference product ^{24Reference 24Seidl LF · 2024In vitroComparing the biological activity and composition of Cerebrolysin with other peptide preparations — in vitro / composition analysisView study →} — so “it says Cerebrolysin on the ampoule” is not an identity guarantee. Uniquely among the peptides here, it also carries an animal-tissue origin: it is made from purified porcine brain, which raises theoretical transmissible-agent concerns that simply do not apply to synthetic peptides. Third-party certificates of analysis and sterility testing are the bare minimum a buyer would want, and even those cannot substitute for pharmaceutical-grade manufacturing under regulatory inspection. This page does not recommend or link vendors.

Safety

Cerebrolysin is usually summarized as well tolerated, but the most rigorous review of it found a probable increase in non-fatal serious adverse events — so a benign profile should not be assumed from the “well tolerated” shorthand.

Safety at a Glance

❔ Toxicity unknownAllergy riskDrug interactions

• Adverse-event rates broadly similar to placebo. That is the pattern across the stroke-recovery and dementia trials.
• Probable increase in non-fatal serious adverse events. The 2023 Cochrane acute-ischemic-stroke review found this at moderate certainty, more pronounced at higher cumulative dose.
• Labeled contraindications. Severe renal impairment, status epilepticus and known hypersensitivity, with caution advised in epilepsy.
• Allergic reaction is a mechanistic concern. The preparation is protein-derived, from purified porcine brain tissue.
• Interaction cautions are label-based. MAO inhibitors, and mixing in the same infusion with certain solutions or amino-acid infusions.
• Parenteral-only, physician-administered. Self-administration is off-label by definition and the highest-risk way to use it.

Full Safety & Interactions Detail

Overall posture. In controlled trials Cerebrolysin has generally been reported as well tolerated, with adverse-event rates broadly similar to placebo in stroke-recovery and dementia studies. The most important safety finding runs the other way: the 2023 Cochrane acute-ischemic-stroke review found, at moderate certainty, a probable increase in non-fatal serious adverse events, more pronounced at the 30 mL/day-for-10-days (300 mL cumulative) schedule, even though total serious adverse events and mortality were unchanged ^{1Reference 1Ziganshina LE et al. · 2023Systematic reviewCerebrolysin for acute ischaemic stroke — human (systematic review, Cochrane)View study →}. A benign safety profile should therefore not be assumed from the “well tolerated” summaries. Reported reactions where they occur include injection-site effects, dizziness, agitation or restlessness, and rare hypersensitivity; because the preparation is protein-derived, allergic reaction is a mechanistic concern rather than a hypothetical one.

Dose-limiting / population cautions. The non-fatal serious-adverse-event signal at higher cumulative doses is the practical dose limiter ^{1Reference 1Ziganshina LE et al. · 2023Systematic reviewCerebrolysin for acute ischaemic stroke — human (systematic review, Cochrane)View study →}. The manufacturer’s labeling contraindicates use in severe renal impairment, status epilepticus, and known hypersensitivity to the preparation, and advises caution in epilepsy given the neurostimulatory profile. Pediatric use appears in two small trials ^{20,21Reference 20Nasiri J · 2017RCTEffect of Cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial — human (RCT, paediatric)View study →Reference 21Samir A et al. · 2022RCTEffect of Cerebrolysin on neurodevelopmental outcome of high-risk preterm infants: a randomized controlled trial — human (RCT, paediatric)View study →} but is not established practice on that evidence.

Interactions. Controlled interaction data are limited. Manufacturer labeling cautions against combining Cerebrolysin with MAO inhibitors (a theoretical additive adrenergic risk) and against mixing it in the same infusion with certain solutions or amino-acid infusions. The one deliberately studied combination is with donepezil in Alzheimer’s disease, where co-administration was reported as safe ^{16Reference 16Alvarez XA et al. · 2011RCTCombination treatment in Alzheimer’s disease: results of a randomized, controlled trial with Cerebrolysin and donepezil — human (RCT)View study →}. Beyond that, interactions have not been formally assessed.

Injection-specific risks. As a parenteral-only product, every standard injection hazard applies — non-sterile technique, contamination, infection, injection-site reactions — and each is amplified when the product is gray-market rather than pharmacy-dispensed, or when the concentration or identity of the ampoule cannot be verified ^{24Reference 24Seidl LF · 2024In vitroComparing the biological activity and composition of Cerebrolysin with other peptide preparations — in vitro / composition analysisView study →}.

Who should avoid it. Anyone who is pregnant, breastfeeding, or trying to conceive; anyone with severe renal impairment, status epilepticus, or known hypersensitivity to the preparation; and anyone considering self-administration, which is off-label by definition for a physician-administered injectable and is the highest-risk way to use this compound.

Scope disclosure (honesty, not a claim):

• Human data? Yes — an unusually large human trial base for a peptide (dozens of RCTs and multiple Cochrane reviews), but geographically concentrated and largely manufacturer-supported.
• Interactions assessed? Partially. Donepezil co-administration was studied; MAOI and infusion-compatibility cautions are label-based; most other interactions have not been formally assessed.
• Pregnancy/lactation assessed? No — no adequate human data exist.
• Long-term safety established? No. Trials are course-based over weeks; chronic or repeated-course long-term safety is unstudied, and the higher-dose non-fatal serious-adverse-event signal is unresolved.

Never imply safety from silence. Where Cerebrolysin has not been studied — long-term use, most interactions, pregnancy, gray-market product identity — the correct statement is “not assessed,” not “safe.”

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not established. There are no adequate controlled data in human pregnancy or lactation, and manufacturer labeling advises against use in pregnancy unless clearly necessary. Treat as contraindicated by default; do not assume safety.

Dosage

There is no self-administration dose for Cerebrolysin, and none is given here. It is a physician-administered prescription injectable where it is approved at all, and an unapproved injectable everywhere else; every figure below is trial data reported for context, not a recommendation or a protocol.

Across the trials here, regimens were courses rather than continuous dosing. Stroke rehabilitation used 30 mL/day IV for 21 days alongside a standardized rehab program (CARS) ^{4Reference 4Muresanu DF et al. · 2016RCTCerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial — human (RCT)View study →}. Traumatic brain injury used 50 mL/day IV for 10 days followed by two further 10 mL/day cycles (CAPTAIN) ^{9,10Reference 9Poon W et al. · 2020RCTSafety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — human (RCT)View study →Reference 10Muresanu DF et al. · 2020RCTEfficacy and safety of Cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial — human (RCT)View study →}. Vascular dementia and Alzheimer’s trials used 20–30 mL/day IV over comparable courses ^{13,14Reference 13Guekht AB et al. · 2011RCTCerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial — human (RCT)View study →Reference 14Gauthier S et al. · 2015Meta-analysisCerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials — human (meta-analysis)View study →}. The pediatric cerebral-palsy trial used 0.1 mL/kg IM ^{20Reference 20Nasiri J · 2017RCTEffect of Cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial — human (RCT, paediatric)View study →}. The practical range across indications is therefore 10–50 mL/day for 10–21 days, sometimes repeated — but the higher cumulative exposures are exactly where Cochrane located the increased non-fatal serious-adverse-event signal ^{1Reference 1Ziganshina LE et al. · 2023Systematic reviewCerebrolysin for acute ischaemic stroke — human (systematic review, Cochrane)View study →}, so “more” is not established as better and may be worse. There is no oral dose, because there is no oral route that works (see Pharmacokinetics). This entry is informational only.

References

1. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. (2023). Cerebrolysin for acute ischaemic stroke — human (systematic review, Cochrane). Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/37818733/
2. Cui S, Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. (2019). Cerebrolysin for vascular dementia — human (systematic review, Cochrane). Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/31710397/
3. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. (2013). Cerebrolysin for vascular dementia — human (systematic review, Cochrane). Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/23440834/
4. Muresanu DF, et al. (2016). Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial — human (RCT). Stroke. https://pubmed.ncbi.nlm.nih.gov/26564102/
5. Guekht A, et al. (2017). Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials — human (meta-analysis). Neurological Sciences. https://pubmed.ncbi.nlm.nih.gov/28707130/
6. Bornstein NM, et al. (2018). Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials — human (meta-analysis). Neurological Sciences. https://pubmed.ncbi.nlm.nih.gov/29248999/
7. Heiss WD, et al. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial — human (RCT). Stroke. https://pubmed.ncbi.nlm.nih.gov/22282884/
8. Zhang D, et al. (2017). Efficacy and safety of Cerebrolysin for acute ischemic stroke: a meta-analysis of randomized controlled trials — human (independent meta-analysis). BioMed Research International. https://pubmed.ncbi.nlm.nih.gov/28656143/
9. Poon W, et al. (2020). Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I — human (RCT). Neurological Sciences. https://pubmed.ncbi.nlm.nih.gov/31494820/
10. Muresanu DF, et al. (2020). Efficacy and safety of Cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial — human (RCT). Neurological Sciences. https://pubmed.ncbi.nlm.nih.gov/31897941/
11. Vester JC, et al. (2021). Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series — human (meta-analysis). Neurological Sciences. https://pubmed.ncbi.nlm.nih.gov/33620612/
12. Jarosz K, et al. (2023). Cerebrolysin in patients with TBI: systematic review and meta-analysis — human (systematic review). Brain Sciences. https://pubmed.ncbi.nlm.nih.gov/36979317/
13. Guekht AB, et al. (2011). Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial — human (RCT). Journal of Stroke and Cerebrovascular Diseases. https://pubmed.ncbi.nlm.nih.gov/20656516/
14. Gauthier S, et al. (2015). Cerebrolysin in mild-to-moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials — human (meta-analysis). Dementia and Geriatric Cognitive Disorders. https://pubmed.ncbi.nlm.nih.gov/25832905/
15. Alvarez XA, et al. (2006). A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease — human (RCT). European Journal of Neurology. https://pubmed.ncbi.nlm.nih.gov/16420392/
16. Alvarez XA, et al. (2011). Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with Cerebrolysin and donepezil — human (RCT). Current Alzheimer Research. https://pubmed.ncbi.nlm.nih.gov/21679156/
17. Ruether E, et al. (2001). A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease — human (RCT). International Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/11552768/
18. Kojder K, et al. (2023). Cerebrolysin in patients with subarachnoid hemorrhage: a systematic review and meta-analysis — human (meta-analysis). Journal of Clinical Medicine. https://pubmed.ncbi.nlm.nih.gov/37892776/
19. Woo PYM, et al. (2020). Randomized, placebo-controlled, double-blind pilot trial to investigate safety and efficacy of Cerebrolysin in patients with aneurysmal subarachnoid hemorrhage — human (pilot RCT). BMC Neurology. https://pubmed.ncbi.nlm.nih.gov/33143640/
20. Nasiri J, Safavifar F. (2017). Effect of Cerebrolysin on gross motor function of children with cerebral palsy: a clinical trial — human (RCT, paediatric). Acta Neurologica Belgica. https://pubmed.ncbi.nlm.nih.gov/28074392/
21. Samir A, et al. (2022). Effect of Cerebrolysin on neurodevelopmental outcome of high-risk preterm infants: a randomized controlled trial — human (RCT, paediatric). Journal of Neonatal-Perinatal Medicine. https://pubmed.ncbi.nlm.nih.gov/33935111/
22. Dong HY, et al. (2016). Cerebrolysin improves sciatic nerve dysfunction in a mouse model of diabetic peripheral neuropathy — animal (mouse). Neural Regeneration Research. https://pubmed.ncbi.nlm.nih.gov/26981106/
23. Rejdak K, et al. (2023). Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of Cerebrolysin — review. Medicinal Research Reviews. https://pubmed.ncbi.nlm.nih.gov/37052231/
24. Seidl LF, Aigner L. (2024). Comparing the biological activity and composition of Cerebrolysin with other peptide preparations — in vitro / composition analysis. Journal of Medicine and Life. https://pubmed.ncbi.nlm.nih.gov/38737662/

View all 24 references▾